Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/resistance-to-anti-cancer-therapeutics-targeting-receptor-tyrosine-kinases-and-downstream-pathways/descriptif_3855900
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3855900

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways, 1st ed. 2018 Resistance to Targeted Anti-Cancer Therapeutics Series, Vol. 15

Langue : Anglais

Coordonnateurs : Yarden Yosef, Elkabets Moshe

Couverture de l’ouvrage Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer

Examines specific targets and the cognate drugs

Evaluates molecular modes of innate and evolving resistance

Date de parution :

Ouvrage de 242 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

158,24 €

Ajouter au panier

Date de parution :

Ouvrage de 242 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

158,24 €

Ajouter au panier

Thème de Resistance to Anti-Cancer Therapeutics Targeting... :